Efficacy and Safety of Immune Checkpoint Inhibitors (ICI) in Resectable Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis

被引：0
|
作者：
Xiao, T. [1 ]
Verma, S. [1 ]
Boldt, G. [1 ]
Rajeh, A. [1 ]
Breadner, D. [2 ]
Raphael, J. [3 ]
机构：
[1] Western Univ, London, ON, Canada
[2] LRCP, London, ON, Canada
[3] Western Univ, London Hlth Sci Ctr, London, ON, Canada
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
103
引用
收藏
页码：E6 / E6
页数：1
相关论文
共 50 条
  • [21] Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
    Guaitoli, Giorgia
    Tiseo, Marcello
    Di Maio, Massimo
    Friboulet, Luc
    Facchinetti, Francesco
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (06) : 2890 - 2916
  • [22] Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis
    Giustozzi, Michela
    Becattini, Cecilia
    Roila, Fausto
    Agnelli, Giancarlo
    Mandala, Mario
    CANCER TREATMENT REVIEWS, 2021, 100
  • [23] Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
    Wang, Shuai
    Hao, Jiatao
    Wang, Hao
    Fang, Yong
    Tan, Lijie
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [24] Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
    Hong, Shaodong
    Tan, Min
    Wang, Shouzheng
    Luo, Shengyuan
    Chen, Yue
    Zhang, Li
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (05) : 909 - 921
  • [25] Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
    Shaodong Hong
    Min Tan
    Shouzheng Wang
    Shengyuan Luo
    Yue Chen
    Li Zhang
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 909 - 921
  • [26] The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis
    Kang, Jing
    Zhang, Jun
    Tian, Zongsheng
    Xu, Ye
    Li, Jiangbi
    Li, Mingxian
    PLOS ONE, 2024, 19 (02):
  • [27] Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis
    Chen, Rui
    Hou, Xiaoming
    Yang, Liping
    Zhao, Da
    THORACIC CANCER, 2019, 10 (04) : 607 - 623
  • [28] The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis
    S.-Y. Zheng
    H.-J. Cui
    H. Duan
    Y.-M. Peng
    Q. Li
    C.-Y. Sun
    J.-Y. Zhang
    W. Shen
    X. Zhang
    K. Tan
    X. Jiang
    Clinical and Translational Oncology, 2020, 22 : 1146 - 1154
  • [29] The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis
    Zheng, S. -Y.
    Cui, H. -J.
    Duan, H.
    Peng, Y. -M.
    Li, Q.
    Sun, C. -Y.
    Zhang, J. -Y.
    Shen, W.
    Zhang, X.
    Tan, K.
    Jiang, X.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (07): : 1146 - 1154
  • [30] The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review
    Chai, Qing-Qing
    Du, Jiang-Yang
    Zhu, Jun
    Wu, Bin
    FRONTIERS IN PHARMACOLOGY, 2019, 10
12345